FindTrial
Sign In

A Retrospective Analysis of Comorbid Chronic Kidney Disease and Knee Osteoarthritis and the Clinical Use of Bushen Jiangu Formula?

Analysis of the Comorbidity of Knee Osteoarthritis and Chronic Kidney Disease and the Study on the Role of Bushen Jiangu Decoction in Regulating Renal Exosomes for the Prevention and Treatment of Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001866
Enrollment
Unknown
Registered
2025-09-28
Start date
2026-03-10
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease / Knee Osteoarthritis

Interventions

NA:NA

Sponsors

Affiliated Hospital of Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Topic 1 Inclusion Criteria: Meet the diagnostic criteria for both Chronic Kidney Disease and Knee Osteoarthritis, with complete diagnostic data including X-ray findings. Have a clearly documented stage of Chronic Kidney Disease. Age range =18 and =85 years. Topic 2 Inclusion Criteria: Meet the diagnostic criteria for both Chronic Kidney Disease and Knee Osteoarthritis, with complete diagnostic data. Have a clearly documented stage of Chronic Kidney Disease. Have complete records of clinical efficacy evaluation indicators for osteoarthritis (e.g., WOMAC score). Age range =18 and =85 years.

Exclusion criteria

Exclusion criteria: Topic 1 : 1. Patients with other severe joint diseases (such as rheumatoid arthritis, gouty arthritis, infectious arthritis, traumatic arthritis, etc.); 2. Patients with stage 5 chronic kidney disease (end-stage renal disease) who have undergone renal replacement therapy; 3. Patients with concurrent malignant tumors; 4. Patients with incomplete clinical data or missing key information. Topic 2 : 1. Patients with other severe joint diseases (such as rheumatoid arthritis, gouty arthritis, infectious arthritis, traumatic arthritis, etc.); 2. Patients with stage 5 chronic kidney disease (end-stage renal disease) who have undergone renal replacement therapy; 3. Patients with concurrent malignant tumors; 4. Patients with incomplete clinical data or missing key information.

Design outcomes

Primary

MeasureTime frame
K-L Grade;Poor prognosis;—

Countries

China

Contacts

Public ContactMingpeng Shi

Affiliated Hospital of Changchun University of Chinese Medicine

dr.shimingpeng@qq.com18043966306

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026